Advertisement

Topics

GeNeuro SA Company Profile

18:02 EDT 20th September 2018 | BioPortfolio


News Articles [10 Associated News Articles listed on BioPortfolio]

GeNeuro Publishes the English Version of Its 2017 Registration Document

Regulatory News: GeNeuro (Euronext Paris: CH0308403085 GNRO) (Paris: GNRO), a biopharmaceutical company developing new treatments for autoimmune diseases, including multiple sclerosis and Type 1 d...

Positive Phase IIb results under GeNeuro and Servier MS collaboration

GeNeuro and French independent pharma company Servier today announced positive results at 12 months from…

GeNeuro to Present New Data Supporting Role of Human Endogenous Retroviruses in Type 1 Diabetes at American Diabetes Association's (ADA) 78th Scientific Sessions

Regulatory News: GeNeuro (Paris:GNRO) (Euronext Paris: CH0308403085 GNRO), a biopharmaceutical company developing new treatments for neurological and autoimmune diseases, including multiple sclero...

Attacking an Ancient Virus Slows Multiple Sclerosis in Phase II

GeNeuro has released Phase IIb data showing that its antibody can reduce brain damage in patients with multiple sclerosis by going after an unusual target: a virus that has been in our genome since an...

GeNeuro reports 12-month Phase IIb data for RRMS candidate

GeNeuro: Financial Information and Business Update for the Second Quarter 2018

Q2 2018 operating revenues of €4.34 million (+195% vs. Q2 2017) €17.11 million cash at June 30, 2018 6-month results for Type 1 Diabetes clinical trial expected end September 2018 Regulatory News:...

GeNeuro SA GNRO Financial and Strategic SWOT Analysis Review [Report Updated: 09032018] Prices from USD $300

SummaryGeNeuro SA GeNeuro is a clinical stage pharmaceutical company that manufactures therapeutic product pipeline for disorders of the nervous system. The company provides treatments against inflamm...

Moving the Needle Forward on Multiple Sclerosis Research (Webinar)

Are we closer to finding a cure for MS? Attend this webinar to find out. July 11, 2018 | 10:00am ET Discover insights from the experts at GeNeuro, a clinical stage pharmaceutical company developi...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [2 Associated Companies listed on BioPortfolio]

GeNeuro

GeNeuro is a Swiss-based company created by Eclosion in 2006 as a spin-off of bioMérieux and co-funded by Eclosion and the Institut Mérieux. GeNeuro is developing first-in-c...

GeNeuro SA

More Information about "GeNeuro SA" on BioPortfolio

We have published hundreds of GeNeuro SA news stories on BioPortfolio along with dozens of GeNeuro SA Clinical Trials and PubMed Articles about GeNeuro SA for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of GeNeuro SA Companies in our database. You can also find out about relevant GeNeuro SA Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record